These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33137282)

  • 21. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials.
    Casula M; Olmastroni E; Boccalari MT; Tragni E; Pirillo A; Catapano AL
    Pharmacol Res; 2019 May; 143():143-150. PubMed ID: 30926528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
    Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
    Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis.
    Qin J; Liu L; Su XD; Wang BB; Fu BS; Cui JZ; Liu XY
    Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2234-2243. PubMed ID: 34052073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
    Laufs U; Birkenfeld AL; Fraass U; Hohenstein B; Siegert C; Klotsche J; Steinhagen-Thiessen E; Pittrow D; Dexl S; Salmen S; Schettler VJJ; Parhofer KG;
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):119-129. PubMed ID: 36178485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
    Arbel R; Hammerman A; Triki N; Greenberg D
    Int J Cardiol; 2016 Oct; 220():242-5. PubMed ID: 27389448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention　- A Meta-Analysis of 12 Randomized Trials.
    Wang S; Xiu J; Liao W; Liao Y; Bin J
    Circ J; 2019 May; 83(6):1356-1367. PubMed ID: 31006730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Dana T; Blazina I; Daeges M; Jeanne TL
    JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis.
    Vlachopoulos C; Terentes-Printzios D; Georgiopoulos G; Skoumas I; Koutagiar I; Ioakeimidis N; Stefanadis C; Tousoulis D
    Atherosclerosis; 2016 Sep; 252():50-60. PubMed ID: 27501130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
    Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
    Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS
    JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
    McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
    J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
    Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.